Lexaria Deepens GLP-1 Focus With DehydraTECH Advances, Patents and Fresh Capital

Lexaria Bioscience ( (LEXX) ) has provided an update.

Lexaria’s CEO reported that in 2025 the company concentrated almost all of its efforts on applying its DehydraTECH oral drug-delivery technology to the three leading GLP-1 drugs—semaglutide, tirzepatide and liraglutide—through multiple human and animal studies that showed encouraging safety, pharmacokinetic, weight-loss, blood-glucose, insulin, biodistribution and blood-pressure outcomes. During the year, Lexaria completed its first registrational Phase 1b study in Australia, expanded its patent portfolio to 56 issued patents including new GLP-1–related protections, extended an evaluation agreement with a pharmaceutical partner, and raised $9.5 million in equity, positioning the company to capitalize on surging global GLP-1 demand and a largely underpenetrated oral segment where it aims to reduce adverse events and improve efficacy for some of the world’s best-selling drugs.

The most recent analyst rating on (LEXX) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.

More about Lexaria Bioscience

Lexaria Bioscience Corp., based in Kelowna, British Columbia, is a drug-delivery technology company specializing in its proprietary DehydraTECH platform, which is designed to enhance oral delivery, tolerability and effectiveness of active pharmaceutical ingredients. The company is increasingly focused on partnering with major pharmaceutical firms and targeting high-growth therapeutic areas, particularly glucagon-like peptide-1 (GLP-1) drugs used in diabetes, obesity and related metabolic and cardiovascular conditions.

Average Trading Volume: 640,145

Technical Sentiment Signal: Sell

Current Market Cap: $17.3M

For an in-depth examination of LEXX stock, go to TipRanks’ Overview page.